TransCode Therapeutics Begins Dosing Patients in Phase 1 Trial for Metastatic Cancer Therapy

Proactive - Interviews for investors

TransCode Therapeutics CEO Tom Fitzgerald joined Steve Darling from Proactive to announce a major milestone: the dosing of the first two patients in the company’s Phase 1 clinical trial for its lead candidate, TTX-MC138. This clinical trial is a multicenter, open-label, dose-escalation, and dose-expansion study designed to evaluate the safety and tolerability of TTX-MC138 in patients with metastatic solid cancers. Several additional patients have already been screened for enrollment in this trial, which could revolutionize cancer treatment. TransCode’s TTX-MC138 is the first therapeutic candidate in clinical development aimed specifically at targeting a molecule linked to metastatic disease, regardless of the cancer's location. The drug has the potential to positively impact patient outcomes across a range of cancers, including breast, pancreatic, ovarian, colon, and lung cancers. The trial is being conducted in two phases. The dose-escalation phase will assess the safety and tolerability of increasing dose levels of TTX-MC138. Once this phase is complete, the dose-expansion phase will focus on evaluating the safety, tolerability, and anti-tumor activity of TTX-MC138 in specific tumor types, selected based on preliminary findings. This breakthrough represents a critical step toward developing an effective treatment for metastatic cancers and offers hope for improving outcomes in some of the most challenging cancer cases. #proactiveinvestors transcodetherapeuticsin #nasdaq #rnaz #RNAtherapeutics #TranscodeTherapeutics #MetastaticCancer #OncologyResearch #TTXMC138 #BiotechInnovation #ClinicalTrials #CancerResearch #TomFitzgerald#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews